✨ Unlock Data Exports And Disclosure Access.Start Your 30-Day Free Trial Today →

Dizal Pharmaceutical Co Ltd

Common Name
Dizal Pharmaceutical
Country
China (Mainland)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,009
Ticker
688192
Exchange
Shanghai Stock Exchange
Description
Dizal (Jiangsu) Pharmaceutical Co., Ltd. specializes in the research, development, and commercialization of innovative therapeutics, focusing primarily on oncology and immunological diseases. As a pha...

Dizal Pharmaceutical's GHG Emissions Data Preview

In 2026, Dizal Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Dizal Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2026202520242023-2019
Total Scope 1
531.5a
886.5a
912.7a
Total Scope 2
Unspecified Calculation Method
5,865.4a
7,066.7a
2,540.2a
Total Scope 3
N/AN/AN/A
Total Scope 1 Revenue Intensity (tCO2e/$M)
N/A
7.7468a
18.5078a
Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=688192&reporting_period=2026"

Verified Sources Behind Dizal Pharmaceutical’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Dizal Pharmaceutical's Prospectus 2025
a. Dizal Pharmaceutical's Prospectus 2025

Insights into Dizal Pharmaceutical's Operational Emissions

In 2026, the total operational greenhouse gas (GHG) emissions of Dizal Pharmaceutical amounted to 6,396.9 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2025, the total operational greenhouse gas (GHG) emissions of Dizal Pharmaceutical decreased by 19.57%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Dizal Pharmaceutical's Scope 1 Emissions Over Time

202320242025202603006009001.2 ktCO2e-15%-3%-40%
  • Total Scope 1
  • Year-over-Year Change

What are Dizal Pharmaceutical's Scope 1 emissions?

In 2026, the total Scope 1 emissions of Dizal Pharmaceutical were 531.5 metric tons of CO₂ equivalent (tCO₂e).a

Has Dizal Pharmaceutical reduced its Scope 1 emissions over time?

Since 2023, Dizal Pharmaceutical's Scope 1 emissions have decreased by 50.76%, reflecting a declining long-term trend in Scope 1 emissions over time.a

Compared to the previous year (2025), Dizal Pharmaceutical's Scope 1 emissions decreased by 40.05%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a

What are Dizal Pharmaceutical's Scope 2 emissions?

In 2026, Dizal Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 5,865.4 tCO₂e without specifying the calculation method.a

Has Dizal Pharmaceutical reduced its Scope 2 emissions over time?

Since 2023, Dizal Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 133.12%, reflecting a rising long-term trend in Scope 2 emissions over time.a

Compared to the previous year (2025), Dizal Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) fell by 17% in 2026, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a

What methodology does Dizal Pharmaceutical use for Scope 2 reporting?

In 2026, Dizal Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a

Dizal Pharmaceutical's Scope 2 Emissions Over Time

202320242025202602 k4 k6 k8 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Dizal Pharmaceutical’s GHG Emissions Intensity Compared to Industry Peers

In 2025, Dizal Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 886.5 tCO₂e and total revenues of USD 114 millions. This translates into an emissions intensity of 7.75 tCO₂e per millions USD.a

Dizal Pharmaceutical's Scope 1 Emissions Intensity Compared to Peers

102002,00050,0001,000,000Scope 1 Emissions (tCO2e)5502002,00010,000Revenues (Millions of USD)Sichuan Biokin PharmaceuticalYear: 2025Scope 1: 8,090 tCO2eRevenue: $M 360Scope 1 Intensity: 22.48 tCO2e/$MHansoh Pharmaceutical GroupYear: 2025Scope 1: 11,834 tCO2eRevenue: $M 2,147Scope 1 Intensity: 5.51 tCO2e/$MJiangsu Hengrui PharmaceuticalsYear: 2025Scope 1: 54,874 tCO2eRevenue: $M 4,518Scope 1 Intensity: 12.15 tCO2e/$MHepalinkYear: 2025Scope 1: 13,483 tCO2eRevenue: $M 777Scope 1 Intensity: 17.36 tCO2e/$MBioKangtaiYear: 2025Scope 1: 15,001 tCO2eRevenue: $M 382Scope 1 Intensity: 39.29 tCO2e/$MJoincareYear: 2025Scope 1: 219,583 tCO2eRevenue: $M 2,173Scope 1 Intensity: 101.03 tCO2e/$MCR Double-CraneYear: 2024Scope 1: 58,155 tCO2eRevenue: $M 1,536Scope 1 Intensity: 37.86 tCO2e/$MChengdu Kanghong Pharmaceutical GroupYear: 2025Scope 1: 11,555 tCO2eRevenue: $M 655Scope 1 Intensity: 17.64 tCO2e/$MBetta PharmaceuticalsYear: 2025Scope 1: 1,268 tCO2eRevenue: $M 516Scope 1 Intensity: 2.46 tCO2e/$MWalvax BiotechnologyYear: 2024Scope 1: 7,643 tCO2eRevenue: $M 387Scope 1 Intensity: 19.77 tCO2e/$MTasly Pharmaceutical GroupYear: 2024Scope 1: 37,370 tCO2eRevenue: $M 1,164Scope 1 Intensity: 32.09 tCO2e/$MApeloa PharmaceuticalYear: 2025Scope 1: 75,760 tCO2eRevenue: $M 1,397Scope 1 Intensity: 54.21 tCO2e/$MZhejiang Huahai PharmaceuticalYear: 2024Scope 1: 58,691 tCO2eRevenue: $M 1,308Scope 1 Intensity: 44.86 tCO2e/$MLivzon Pharmaceutical GroupYear: 2025Scope 1: 175,562 tCO2eRevenue: $M 1,717Scope 1 Intensity: 102.25 tCO2e/$MChangchun High-TechYear: 2025Scope 1: 133,335 tCO2eRevenue: $M 1,726Scope 1 Intensity: 77.25 tCO2e/$MSimcere Pharmaceutical GroupYear: 2025Scope 1: 5,428 tCO2eRevenue: $M 1,104Scope 1 Intensity: 4.92 tCO2e/$MHumanwell Healthcare (Group)Year: 2025Scope 1: 24,083 tCO2eRevenue: $M 3,423Scope 1 Intensity: 7.04 tCO2e/$MDa Ren TangYear: 2025Scope 1: 3,870 tCO2eRevenue: $M 702Scope 1 Intensity: 5.51 tCO2e/$MDong-E-E-JiaoYear: 2024Scope 1: 20,046 tCO2eRevenue: $M 811Scope 1 Intensity: 24.71 tCO2e/$MBeijing Tong Ren TangYear: 2025Scope 1: 28,656 tCO2eRevenue: $M 2,465Scope 1 Intensity: 11.63 tCO2e/$MShenzhen Salubris PharmaceuticalsYear: 2024Scope 1: 11,399 tCO2eRevenue: $M 550Scope 1 Intensity: 20.73 tCO2e/$MChina Resources SanjiuYear: 2025Scope 1: 61,350 tCO2eRevenue: $M 4,514Scope 1 Intensity: 13.59 tCO2e/$MHua MedicineYear: 2023Scope 1: 19 tCO2eRevenue: $M 11Scope 1 Intensity: 1.78 tCO2e/$MCanSino BiologicsYear: 2025Scope 1: 2,121 tCO2eRevenue: $M 151Scope 1 Intensity: 14.02 tCO2e/$MDizal PharmaceuticalYear: 2025Scope 1: 887 tCO2eRevenue: $M 114Scope 1 Intensity: 7.75 tCO2e/$M

How does Dizal Pharmaceutical's GHG emissions intensity compare to its peers?

In 2025, Dizal Pharmaceutical reported a Scope 1 emissions intensity of 7.75 tCO₂e per millions USD. Compared to the peer group median of 18.71, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Dizal Pharmaceutical rank on GHG emissions intensity within its industry?

In 2025, Dizal Pharmaceutical ranked 7 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

Dizal Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Want Full Access to Dizal Pharmaceutical's GHG Emissions Dataset?
Start 30-Day Free Trial